GlassScriptPhysician profile
Laeeq A Khan
NPI 1235139031
$810.63
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $145 · 2020: $35.05 · 2021: $219 · 2022: $77.47 · 2023: $227 · 2024: $106.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $333.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $333.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cranial Technologies, INC | $165.33 | 2019-2024 | Doc Band |
| Ironshore Pharmaceuticals INC. | $114.72 | 2022-2024 | Jornay Pm |
| Glaxosmithkline, LLC. | $107.16 | 2019-2023 | Bexsero, Pediarix, Menveo |
| Abbvie INC. | $75.05 | 2020-2023 | |
| Shire North American Group INC | $62.51 | 2019 | |
| Sanofi Pasteur INC. | $48.30 | 2023 | |
| Pfizer INC. | $39.53 | 2021-2024 | |
| Corium, LLC | $37.66 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $33.36 | 2020-2021 | |
| Tris Pharma INC | $26.49 | 2023 | Dyanavel Xr |
| Sobi, INC | $22.08 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $19.41 | 2021 | |
| Merck Sharp & Dohme LLC | $17.14 | 2024 | Gardasil, Gardasil 9, Vaqta |
| Ultragenyx Pharmaceutical INC. | $16.32 | 2019 | |
| Tolmar Pharmaceuticals, INC. | $13.77 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cumberland Pharmaceuticals, INC. | $11.80 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laeeq Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.